{"organizations": [], "uuid": "4fecc86bcf4859d415ad5bbbfda8ec6ddbbc8b1d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/28/globe-newswire-argos-therapeutics-to-report-fourth-quarter-and-year-end-2017-financial-results-and-operational-highlights-on-monday-april.html", "country": "US", "domain_rank": 767, "title": "Argos Therapeutics to Report Fourth Quarter and Year-End Financial and Operational Highlights on Monday, April 2, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.831, "site_type": "news", "published": "2018-03-29T01:00:00.000+03:00", "replies_count": 0, "uuid": "4fecc86bcf4859d415ad5bbbfda8ec6ddbbc8b1d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/28/globe-newswire-argos-therapeutics-to-report-fourth-quarter-and-year-end-2017-financial-results-and-operational-highlights-on-monday-april.html", "ord_in_thread": 0, "title": "Argos Therapeutics to Report Fourth Quarter and Year-End Financial and Operational Highlights on Monday, April 2, 2018", "locations": [], "entities": {"persons": [{"name": "argos", "sentiment": "none"}], "locations": [{"name": "durham", "sentiment": "none"}, {"name": "n.c.", "sentiment": "none"}], "organizations": [{"name": "argos therapeutics inc.", "sentiment": "negative"}, {"name": "argos therapeutics", "sentiment": "negative"}, {"name": "argos therapeutics argos therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it will report fourth quarter and year-end 2017 financial results and operational highlights prior to the market open on Monday, April 2, 2018.\nAbout Argos Therapeutics\nArgos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, Rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication.\nInvestor Contact:\nRichard Katz, MD, MBA\nArgos Therapeutics, Inc.\n919-287-6315\nrkatz@argostherapeutics.com\nMedia Contact:\nAdam Daley\nBerry & Company Public Relations\n212.253.8881\nadaley@berrypr.com\nSource:Argos Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/1369dc8c-4faf-45e0-a233-d6487a918805"], "published": "2018-03-29T01:00:00.000+03:00", "crawled": "2018-03-29T00:48:57.002+03:00", "highlightTitle": ""}